Researchers followed kidney cancer patients who had received cryoablation for three yearswell beyond the established and well-accepted one-year benchmark within the medical community to gauge the success of a kidney tumor treatment optionsince most kidney tumors would be visible within a year with a CT scan or MRI. The use of percutaneous cryoablation should not be limitedas it has beento patients who have other diseases that make surgery very high risk, cannot undergo anesthesia, have borderline kidney function, may only have one kidney or multiple recurring tumors or do not have any other option, said Georgiades. "There may be a bias in the medical communityamong surgeons, primary care doctors and urologiststhat cryoablation works only for certain patients with small tumors. This is not the case," emphasized Georgiades.
"Traditionally, laparoscopic surgery has been the main treatment option for all renal cell cancers; it literally cuts the cancer out. The good news is that individuals no longer need to have a kidney partially or completed removed to treat their cancer," noted Georgiades. When comparing the rate of complications between percutaneous cryoablation and surgery, Georgiades said that none of the patients who had cryoablation developed new or metastatic disease and they had fewer complications. The minimally invasive nature of interventional cryoablation means that it can be performed with minimal blood loss and without
|Contact: Maryann Verrillo|
Society of Interventional Radiology